A Pilot Study to Evaluate the Safety of Subcutaneous Alemtuzumab (MabCampath, Campath) in Patients With B-Cell Chronic Lymphocytic Leukemia
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Anders C Osterborg, Professor
Principal Investigator
Dept. of Hematology, Karolinska University Hospital
Sweden: Medical Products Agency
CAM219
NCT00162851
April 2003
July 2006
Name | Location |
---|